Regain d’intérêt pour le contrôle de l’hyperglycémie postprandiale.

Blood Glucose; Glycated Hemoglobin A; Hypoglycemic Agents; Insulin; Blood Glucose Self-Monitoring; Glycated Hemoglobin; Humans; Hypoglycemic Agents/therapeutic use; Insulin/therapeutic use; Postprandial Period; Quality of Life; Diabetes Complications/drug therapy; Diabetes Mellitus/drug therapy; Diabetes Mellitus, Type 2/drug therapy; Hyperglycemia/drug therapy; Hyperglycemia/prevention & control; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hyperglycemia; Medicine (all); General Medicine

Abstract :

[en] Postprandial hyperglycaemia (PPH) may sometimes be relegated to the background in the treatment of diabetic patients, while its control seems important if not essential to reach an adequate overall glycaemic control. PPH is correlated with glycated haemoglobin and diabetic complications. It is also identified as a cardiovascular risk factor. PPH's monitoring and adequate control are not only a therapeutic goal for diabetes itself but also for reducing associated adverse outcomes other than diabetic complications. PPH is related to the quality of life of patients. Continuous glucose monitoring allows a better appraisal of PPH. The use of new insulin formulations as ultra-fast insulins seems to be the better way to manage post-prandial blood glucose peaks.
[fr] L’hyperglycémie postprandiale (HGPP) peut parfois passer au second plan lors de la prise en charge globale du patient diabétique. Néanmoins, sa maîtrise est indispensable pour obtenir un équilibre glycémique global optimal. L’HGPP est corrélée à l’hémoglobine glyquée ainsi qu’aux complications du diabète. Elle semble également jouer un rôle par rapport au risque cardiovasculaire. Outre son intérêt dans la prise en charge thérapeutique du diabète proprement dit, l’HGPP doit être maîtrisée en raison de son lien avec d’autres conséquences médicales et de son impact négatif sur la qualité de vie des patients. Le monitoring continu du glucose permet une meilleure appréciation de l’HGPP. Les nouvelles insulines ultra-rapides paraissent être les molécules les plus adéquates pour réduire, au mieux et au plus vite, l’HGPP.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Vandelaer, Antoine ; Département de médecine interne > Service de cardiologie

Joubert, Michael; Service d'endocrinologie-diabétologie, CHU de Caen, 14000 Caen, France

Philips, Jean-Christophe ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

Language :

French

Title :

Regain d’intérêt pour le contrôle de l’hyperglycémie postprandiale.

Alternative titles :

[en] Renewed interest for the control of post-prandial hyperglycaemia.

Publication date :

24 August 2022

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Editions Medecine et Hygiene, Switzerland

Volume :

Issue :

792

Pages :

1560 - 1564

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 24 December 2023

Statistics

Number of views

18 (0 by ULiège)

Number of downloads

15 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

American Diabetes Association Professional Practice, Committee. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45 (Suppl 1):S83-96.
Joubert M, Meyer L, Doriot A, et al. Prospective Independent Evaluation of the Carbohydrate Counting Accuracy of Two Smartphone Applications. Diabetes Ther. 2021; 12(7):1809-12.
Haak T, Herrmann E, Lippmann-Grob B, et al. The Effect of Prandial Insulin Applied for Fat Protein Units on Postprandial Glucose Excursions in Type 1 Diabetes Patients with Insulin Pump Therapy: Results of a Randomized, Controlled, Cross-Over Study. Exp Clin Endocrinol Diabetes. 2022; 130(4):262-7.
Faber EM, van Kampen PM, Clementde Boers A, et al. The influence of food order on postprandial glucose levels in children with type 1 diabetes. Pediatr Diabetes. 2018; 19(1):809-15.
Lehmann V, Zueger T, Zeder A, et al. Lower Daily Carbohydrate Intake Is Associated with Improved Glycemic Control in Adults with Type 1 Diabetes Using a Hybrid Closed-Loop System. Diabetes Care. 2020; 43(12):3102-5.
Ryan RL, King BR, Anderson DG, et al. Influence of and optimal insulin therapy for a low-glycemic index meal in children with type 1 diabetes receiving intensive insulin therapy. Diabetes Care. 2008; 31(8):1485-90.
Reynolds AN, Mann JI, Williams S, et al. Advice to walk after meals is more effective for lowering postprandial glycaemia in type 2 diabetes mellitus than advice that does not specify timing: a randomised crossover study. Diabetologia. 2016; 59(12):2572-8.
Cobry E, McFann K, Messer L, et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010; 12(3):173-7.
Adolfsson P, Hartvig NV, Kaas A, et al. Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen. Diabetes Technol Ther. 2020; 22(10):709-18.
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003; 26(3):881-5.
Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007; 77(2):280-5.
Zhang DA, Katzneslon L, Li M. Postprandial glucose monitoring further improved glycemia, lipids, and weight in persons with type 2 diabetes mellitus who had already reached hemoglobin A1c goal. J Diabetes Sci Technol. 2012; 6(2):289-93.
Lefèbvre PJ, Scheen AJ. Glucose metabolism and the postprandial state. Eur J Clin Invest. 1999; 29 Suppl 2:1-6.
Lefèbvre PJ, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabet Med. 1998; 15 Suppl 4:S63-8.
Aryangat AV, Gerich JE. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vasc Health Risk Manag. 2010; 6:145-55.
Scheen AJ. La dysfonction endothéliale : signification clinique et implications thérapeutiques. Med Mal Metab. 2021; 15(5):496-504.
FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment with Rapid-Acting Insulin Versus GLP-1 Agonist in Participants with Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care. 2016; 39(6):973-81.
Raz I, Wilson PWF, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009; 32(3):381-6.
Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014; 127(10 Suppl):S25-38.
Heise T, Pieber TR, Danne T, et al. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. Clin Pharmacokinet. 2017; 56(5):551-9.
Russell-Jones D, Bode BW, De Block C, et al. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (Onset 1). Diabetes Care. 2017; 40(7):943-50.
Bowering K, Case C, Harvey J, et al. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The Onset 2 Trial. Diabetes Care. 2017; 40(7):951-7.
Bode BW, Johnson JA, Hyveled L, et al. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion. Diabetes Technol Ther. 2017; 19(1):25-33.
Bue-Valleskey J, Klaff L, Cho JI, et al. Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in adults with type 1 diabetes: The PRONTO-T1D Extension. Diabetes Ther. 2021; 12(2):569-80.
Philips JC, Paquot N. Ultra-rapid lispro (Lyumjev®). Rev Med Liege. 2021; 76(1):64-8.
Malecki MT, Cao D, Hardy T, et al. Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy. Diabetes Technol Ther. 2020; 22(11):853-60.
Blevins T, Zhang Q, Frias JP, et al. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro with Lispro in a Basal-Bolus Regimen in Patients with Type 2 Diabetes: PRONTO-T2D. Diabetes Care. 2020; 43(12):2991-8.
Heise T, Linnebjerg H, Coutant D, et al. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obes Metab. 2020; 22(10):1789-98.